Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors
Israeli pharmaceutical company Compugen has announced the commencement of a phase 1 clinical trial for its innovative cancer immunotherapy antibody, COM701, targeting patients with advanced ... Read More
Xencor initiates Phase 1 trial of XmAb20717 for advanced solid tumors
Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed ... Read More